Literature DB >> 17951119

Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry.

J Lee1, H Kim, J C Jeong, E S Park, K W Hwang, S J Yang, J H Jeong.   

Abstract

A simple, rapid, sensitive and specific liquid chromatography-tandem mass spectrometry method was developed and validated for quantification of beraprost, a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. The analyte and internal standard, indomethacin, were extracted by solid-phase extraction using OASIS HLB cartridge. The chromatographic separation was performed on a C18 column with a mobile of 0.1% formic acid-methanol (30:70, v/v). The highest daughter ion of deprotonated analyte was quantitated in negative ionization by multiple reactions monitoring with a mass spectrometer. The mass transitions m/z 397>269 and m/z 356>312 were used to measure beraprost and internal standard, respectively. The assay exhibited a linear range from 0.02 to 2 ng/mL for beraprost in human plasma. The lower limit of quantitation was 20 pg/mL with a relative standard deviation of less than 20%. The method was validated with respect to linearity, sensitivity, specificity, recovery, accuracy and precision. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951119     DOI: 10.1016/j.jchromb.2007.09.034

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  1 in total

1.  Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study.

Authors:  Hajimu Kurumatani; Kiyonobu Okada; Hideki Origasa; Toshiro Fujita; Masanao Isono; Hidetomo Nakamoto
Journal:  Ther Apher Dial       Date:  2021-02-21       Impact factor: 1.762

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.